BTOG wishes to inform members of a new NICE release that has been published today.
NICE has recommended amivantamab with carboplatin and pemetrexed during the managed access period as an option for untreated advanced non-small-cell lung cancer (NSCLC) with activating EGFR exon 20 insertion (ex20ins) mutations in adults. It can only be used if the conditions in the managed access agreement for amivantamab with carboplatin and pemetrexed are followed. This recommendation is not intended to affect treatment with amivantamab with carboplatin and pemetrexed that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS healthcare professional consider it appropriate to stop.
What this means in practice is that NICE, NHS England and Johnson & Johnson have a managed access agreement for amivantamab with carboplatin and pemetrexed. This means it can be used as an option in the NHS in England during the managed access period. During this time, more evidence will be collected to address any uncertainties. After this, NICE will review and update their guidance. Amivantamab with carboplatin and pemetrexed can only be used if the conditions in the managed access agreement are followed.
For full details and the documents, please see the NICE website:
https://www.nice.org.uk/guidance/indevelopment/gid-ta11023/documents
